A Novel Class of Small Molecule Agonists with Preference for Human over Mouse TLR4 Activation

• Jason D. Marshall ,

  * E-mail: jdmarshall67@yahoo.com

  Affiliation Vaccine Platform Group, MedImmune, Gaithersburg, Maryland, United States of America

  ⨯
• Darren S. Heeke,

  Affiliation Translational Biology Group, MedImmune, Mountain View, California, United States of America

  ⨯
• Eileen Rao,

  Affiliation Translational Biology Group, MedImmune, Mountain View, California, United States of America

  ⨯
• Sean K. Maynard,

  Affiliation Vaccine Platform Group, MedImmune, Gaithersburg, Maryland, United States of America

  ⨯
• David Hornigold,

  Affiliation Department of Cardiovascular and Metabolic Diseases, MedImmune, Cambridge, United Kingdom

  ⨯
• Christopher McCrae,

  Affiliation Translational Science, Respiratory, Inflammation and Autoimmunity Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Neil Fraser,

  Affiliation Biology Department, AstraZeneca R&D, Charnwood, United Kingdom

  ⨯
• Andrey Tovchigrechko,

  Affiliation Research Bioinformatics, MedImmune, Gaithersburg, Maryland, United States of America

  ⨯
• Li Yu,

  Affiliation Statistical Sciences, MedImmune, Gaithersburg, Maryland, United States of America

  ⨯
• Nicola Williams,

  Affiliation Biology Department, AstraZeneca R&D, Charnwood, United Kingdom

  ⨯
• Sarah King,

  Affiliation Medicinal Chemistry Department, AstraZeneca R&D, Charnwood, United Kingdom

  ⨯
• Martin E. Cooper,

  Affiliation Translational Science, Respiratory, Inflammation and Autoimmunity Innovative Medicines, AstraZeneca R&D, Mölndal, Sweden

  ⨯
• Adeline M. Hajjar,

  Affiliation Department of Comparative Medicine, University of Washington, Seattle, Washington, United States of America

  ⨯
• Jennifer C. Woo

  Affiliation Translational Biology Group, MedImmune, Mountain View, California, United States of America

  ⨯